Our Early 2012 report detailed several significant catalysts that resulted in double-digit stock price changes, details of which can be found in the table on Page 2 of this report.

Our Q2 2012 report covers a number of catalysts from 22 drugs and 1 device. We have included comprehensive calendars through June 2012 from our sister product, CatalystTracker, of Large Impact catalysts in the drug, device/diagnostic and natural resource areas. Additionally, we have included the drugs’ likelihood of phase/PDUFA review success and overall likelihood of approval (LOA) given their particular phase, drug class, and disease group. Please see the appendix for definitions of these probabilities. Please note the current LOAs displayed on BioMedTracker are not based on this new data; this data will be integrated at a later time.

If you would like a copy of the calendars in Excel, please email clientservices@pharmaintel.informa.com or contact your sales representative.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.